Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials

Abstract Background While indirect comparison of infliximab (IFX) and vedolizumab (VDZ) in adults with Crohn’s disease (CD) or ulcerative colitis (UC) shows that IFX has better effectiveness during induction, and comparable efficacy during maintenance treatment, comparative data specific to subcutan...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Laurent Peyrin‐Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Marc Ferrante, Jordi Guardiola, Jørgen Jahnsen, Edouard Louis, Milan Lukáš, Walter Reinisch, Xavier Roblin, Philip J Smith, Taek Kwon, Jeeyoung Kim, Sangwook Yoon, Dong-Hyeon Kim, Raja Atreya
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: BMC 2024-03-01
Sarja:BMC Gastroenterology
Aiheet:
Biobetter
Bioinnovative
Inflammatory bowel disease
Subcutaneous infliximab
Tumour necrosis factor-α inhibitors
Vedolizumab
Linkit:https://doi.org/10.1186/s12876-024-03163-5

Internet

https://doi.org/10.1186/s12876-024-03163-5

Samankaltaisia teoksia